TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized Trial of Thymoglobulin to Prevent Chronic Graft Versus Host Disease in Patients Undergoing Hematopoietic Progenitor Cell Transplantation (HPCT) From Unrelated Donors
Brief Summary: This is a randomized trial for patients undergoing hematopoietic progenitor cell transplantation (HPCT) from an unrelated donor. Approximately 50% of the patients enrolled will receive Thymoglobulin® as part of the preparative regimen prior to HPCT. The other 50% of the patients enrolled will receive a standard preparative regimen. Thymoglobulin is known to suppress the types of cells that can cause a transplant complication known as "chronic graft versus host disease (cGVHD)". The goal of this trial is to find out if adding Thymoglobulin to the preparative regimen will result in a decrease in cGVHD.


Options:
A: Arm Label: Thymoglobulin; Type: EXPERIMENTAL; Interventions: Biological: Anti-Thymocyte Globulin (Rabbit) | Arm Label: No Thymoglobulin; Type: OTHER; Interventions: Other: Patients will receive a standard preparative regimen (i.e. one that does not contain Thymoglobulin) | Intervention Type: BIOLOGICAL; Name: Anti-Thymocyte Globulin (Rabbit); Assigned to Arm(s): Thymoglobulin | Intervention Type: OTHER; Name: Patients will receive a standard preparative regimen (i.e. one that does not contain Thymoglobulin); Assigned to Arm(s): No Thymoglobulin
B: Arm Label: Ruxolitinib; Type: EXPERIMENTAL; Interventions: Drug: Ruxolitinib (RUX) | Arm Label: Best Available Therapy (BAT); Type: ACTIVE_COMPARATOR; Interventions: Drug: Best Available Therapy (BAT) | Intervention Type: DRUG; Name: Ruxolitinib (RUX); Assigned to Arm(s): Ruxolitinib | Intervention Type: DRUG; Name: Best Available Therapy (BAT); Assigned to Arm(s): Best Available Therapy (BAT)
C: Arm Label: TBI + fludarabine; Type: ACTIVE_COMPARATOR; Interventions: Drug: Conditioning regimen: TBI + Fludarabine | Arm Label: TLI + ATG; Type: ACTIVE_COMPARATOR; Interventions: Drug: Conditioning regimen:TLI (8 Gy) + ATG | Intervention Type: DRUG; Name: Conditioning regimen: TBI + Fludarabine; Assigned to Arm(s): TBI + fludarabine | Intervention Type: DRUG; Name: Conditioning regimen:TLI (8 Gy) + ATG; Assigned to Arm(s): TLI + ATG
D: Arm Label: routine prophylaxis; Type: ACTIVE_COMPARATOR; Interventions: Drug: anti thymoglobulin | Arm Label: ATG prophylaxis; Type: EXPERIMENTAL; Interventions: Drug: anti thymoglobulin | Intervention Type: DRUG; Name: anti thymoglobulin; Assigned to Arm(s): ATG prophylaxis, routine prophylaxis

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Double Blind Placebo Controlled Study of PH94B for Management of the Symptoms of Generalized Social Phobia
Brief Summary: The purpose of this study is to determine the efficacy of PH94B, a new class of therapeutic compound, administered intranasally for the management of acute anxiety in patients diagnosed with generalized social phobia.


Options:
A: Arm Label: Vilazodone; Type: EXPERIMENTAL; Interventions: Drug: Vilazodone | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Vilazodone; Assigned to Arm(s): Vilazodone | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
B: Intervention Type: DRUG; Name: vestipitant; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: paroxetine; Assigned to Arm(s): N/A
C: Intervention Type: DRUG; Name: LY686017; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: paroxetine; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): N/A
D: Arm Label: PH94B intranasal spray; Type: EXPERIMENTAL; Interventions: Drug: PH94B intranasal spray | Arm Label: Placebo intranasal spray; Type: PLACEBO_COMPARATOR; Interventions: Drug: PH94B intranasal spray | Intervention Type: DRUG; Name: PH94B intranasal spray; Assigned to Arm(s): PH94B intranasal spray, Placebo intranasal spray

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Implantable Cardioverter-Defibrillator (ICD) Utilization in a Potentially Eligible VA Population
Brief Summary: Despite being a proven life-saving intervention in appropriately selected individuals, multiple studies continue to demonstrate low implantation of defibrillators in potential candidates. Based upon prior research, a major barrier to low utilization is low referral of potential candidates by healthcare providers. In this study, via brief clinical reminder placed in the electronic medical record, we ask healthcare providers who have not referred potential candidates for defibrillator the reasons for this decision and provide them with the tools for referral if appropriate.


Options:
A: Arm Label: dashboard team care intervention; Type: EXPERIMENTAL; Interventions: Behavioral: Diabetes Dashboard Intervention | Arm Label: usual diabetes team control; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Usual Diabetes Care | Intervention Type: BEHAVIORAL; Name: Diabetes Dashboard Intervention; Assigned to Arm(s): dashboard team care intervention | Intervention Type: BEHAVIORAL; Name: Usual Diabetes Care; Assigned to Arm(s): usual diabetes team control
B: Arm Label: Usual Care; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: STAR - Study of Technology to Accelerate Research | Arm Label: Clinician intervention only; Type: EXPERIMENTAL; Interventions: Behavioral: STAR - Study of Technology to Accelerate Research | Arm Label: Clinician intervention plus Direct-to-parent communication; Type: EXPERIMENTAL; Interventions: Behavioral: STAR - Study of Technology to Accelerate Research | Intervention Type: BEHAVIORAL; Name: STAR - Study of Technology to Accelerate Research; Assigned to Arm(s): Clinician intervention only, Clinician intervention plus Direct-to-parent communication, Usual Care
C: Arm Label: Clinical Reminder; Type: EXPERIMENTAL; Interventions: Behavioral: Clinical Reminder | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Clinical Reminder; Assigned to Arm(s): Clinical Reminder
D: Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: HIT Intervention without feedback; Type: EXPERIMENTAL; Interventions: Other: 3-Part Intervention | Arm Label: HIT Intervention with feedback; Type: EXPERIMENTAL; Interventions: Other: 4-Part Intervention | Arm Label: Feedback only; Type: EXPERIMENTAL; Interventions: Other: 1-part intervention | Intervention Type: OTHER; Name: 3-Part Intervention; Assigned to Arm(s): HIT Intervention without feedback | Intervention Type: OTHER; Name: 4-Part Intervention; Assigned to Arm(s): HIT Intervention with feedback | Intervention Type: OTHER; Name: 1-part intervention; Assigned to Arm(s): Feedback only

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Implantable Cardioverter-Defibrillator (ICD) Utilization in a Potentially Eligible VA Population
Brief Summary: Despite being a proven life-saving intervention in appropriately selected individuals, multiple studies continue to demonstrate low implantation of defibrillators in potential candidates. Based upon prior research, a major barrier to low utilization is low referral of potential candidates by healthcare providers. In this study, via brief clinical reminder placed in the electronic medical record, we ask healthcare providers who have not referred potential candidates for defibrillator the reasons for this decision and provide them with the tools for referral if appropriate.


Options:
A: Arm Label: Clinical Reminder; Type: EXPERIMENTAL; Interventions: Behavioral: Clinical Reminder | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Clinical Reminder; Assigned to Arm(s): Clinical Reminder
B: Arm Label: Intervention group; Type: N/A; Interventions: Behavioral: reminders | Arm Label: current practice group; Type: N/A; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: reminders; Assigned to Arm(s): Intervention group
C: Arm Label: Provider Alert; Type: EXPERIMENTAL; Interventions: Other: Provider Alert | Arm Label: No Alert; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: Provider Alert; Assigned to Arm(s): Provider Alert
D: Arm Label: reminders, no reminder; Type: EXPERIMENTAL; Interventions: Behavioral: reminders vs. no reminders | Intervention Type: BEHAVIORAL; Name: reminders vs. no reminders; Assigned to Arm(s): reminders, no reminder

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A 12 Month, Phase III, Randomized, Double-masked, Multicenter, Active-controlled Study to Evaluate the Efficacy and Safety of Two Different Dosing Regimens of 0.5 mg Ranibizumab vs. Verteporfin PDT in Patients With Visual Impairment Due to Choroidal Neovascularization Secondary to Pathologic Myopia
Brief Summary: This study is designed to evaluate the efficacy and safety of two different dosing regimens of 0.5 mg ranibizumab given as intravitreal injection in comparison to verteporfin PDT in patients with visual impairment due to choroidal neovascularization (CNV) secondary to pathologic myopia (PM).


Options:
A: Arm Label: Ranibizumab driven by disease activity; Type: EXPERIMENTAL; Interventions: Drug: Ranibizumab, Drug: Sham Ranibizumab, Drug: Sham verteporfin PDT | Arm Label: Ranibizumab driven by stabilization criteria; Type: EXPERIMENTAL; Interventions: Drug: Ranibizumab, Drug: Sham Ranibizumab, Drug: Sham verteporfin PDT | Arm Label: Verteporfin PDT; Type: ACTIVE_COMPARATOR; Interventions: Drug: Ranibizumab, Drug: Verteporfin PDT, Drug: Sham Ranibizumab, Drug: Sham verteporfin PDT | Intervention Type: DRUG; Name: Ranibizumab; Assigned to Arm(s): Ranibizumab driven by disease activity, Ranibizumab driven by stabilization criteria, Verteporfin PDT | Intervention Type: DRUG; Name: Verteporfin PDT; Assigned to Arm(s): Verteporfin PDT | Intervention Type: DRUG; Name: Sham Ranibizumab; Assigned to Arm(s): Ranibizumab driven by disease activity, Ranibizumab driven by stabilization criteria, Verteporfin PDT | Intervention Type: DRUG; Name: Sham verteporfin PDT; Assigned to Arm(s): Ranibizumab driven by disease activity, Ranibizumab driven by stabilization criteria, Verteporfin PDT
B: Intervention Type: DRUG; Name: rhuFab V2 (ranibizumab); Assigned to Arm(s): N/A
C: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: ranibizumab | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Drug: bevacizumab | Arm Label: 3; Type: EXPERIMENTAL; Interventions: Drug: ranibizumab | Arm Label: 4; Type: EXPERIMENTAL; Interventions: Drug: bevacizumab | Intervention Type: DRUG; Name: ranibizumab; Assigned to Arm(s): 1, 3 | Intervention Type: DRUG; Name: bevacizumab; Assigned to Arm(s): 2, 4
D: Arm Label: ranibizumab 0.5mg; Type: EXPERIMENTAL; Interventions: Drug: ranibizumab 0.5mg | Intervention Type: DRUG; Name: ranibizumab 0.5mg; Assigned to Arm(s): ranibizumab 0.5mg

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Prospective Randomized Clinical Trial to Determine the Efficacy of 24 Chromosome Preimplantation Genetic Diagnosis
Brief Summary: The purpose of this study is to determine if 24 chromosome preimplantation genetic diagnosis (PGD) increases implantation and delivery rates in couples attempting to conceive through in vitro fertilization (IVF).


Options:
A: Arm Label: A; Type: ACTIVE_COMPARATOR; Interventions: Genetic: single embryo transfer without aneuploidy screening | Arm Label: B; Type: EXPERIMENTAL; Interventions: Genetic: single embryo transfer with aneuploidy screening | Intervention Type: GENETIC; Name: single embryo transfer without aneuploidy screening; Assigned to Arm(s): A | Intervention Type: GENETIC; Name: single embryo transfer with aneuploidy screening; Assigned to Arm(s): B
B: Arm Label: Group A; Type: EXPERIMENTAL; Interventions: Other: Preimplantation Genetic Screening by NGS | Arm Label: Group B; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: Preimplantation Genetic Screening by NGS; Assigned to Arm(s): Group A
C: Arm Label: PGT-A group; Type: ACTIVE_COMPARATOR; Interventions: Procedure: comprehensive chromosome screening | Arm Label: Morphology group; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: PROCEDURE; Name: comprehensive chromosome screening; Assigned to Arm(s): PGT-A group
D: Arm Label: Control (no PGD); Type: N/A; Interventions: N/A | Arm Label: Case (PGD); Type: N/A; Interventions: N/A

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Heparin-bonded Endoluminal Versus Surgical Femoropopliteal Bypass; a Multicentre Randomized Controlled Trial
Brief Summary: In this multicentre Randomized Clinical Trial, the heparin-bonded endoluminal bypass will be compared to the surgical venous femoro-popliteal bypass, based on the non-inferiority principle for the patency. Besides equal patency, an improved quality of life is expected. Recruitment will take the first two years and patients will be followed during five years. Patients with an indication for surgical bypass, classified category 3-6 with a \>50% stenosis or occlusion of the SFA over \>/=10 cm in length will be included. At least one crural artery should be patent without significant lesions.


Options:
A: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Supervised Exercise Therapy, Drug: Cilostazol | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Device: Stent, Drug: Cilostazol | Arm Label: 3; Type: ACTIVE_COMPARATOR; Interventions: Device: Stent, Behavioral: Supervised Exercise Therapy | Intervention Type: DEVICE; Name: Stent; Assigned to Arm(s): 2, 3 | Intervention Type: BEHAVIORAL; Name: Supervised Exercise Therapy; Assigned to Arm(s): 1, 3 | Intervention Type: DRUG; Name: Cilostazol; Assigned to Arm(s): 1, 2
B: Arm Label: Heparin-bonded endoluminal fempop bypass; Type: EXPERIMENTAL; Interventions: Procedure: Heparin-bonded ePTFE endoluminal fem-pop bypass | Arm Label: Surgical femoro-popliteal bypass; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Surgical femoro-popliteal bypass. | Intervention Type: PROCEDURE; Name: Heparin-bonded ePTFE endoluminal fem-pop bypass; Assigned to Arm(s): Heparin-bonded endoluminal fempop bypass | Intervention Type: PROCEDURE; Name: Surgical femoro-popliteal bypass.; Assigned to Arm(s): Surgical femoro-popliteal bypass
C: Arm Label: REA; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Remote endarterectomy of the superficial femoral artery | Arm Label: Bypass; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Suprageniculate femoropopliteal bypass | Intervention Type: PROCEDURE; Name: Remote endarterectomy of the superficial femoral artery; Assigned to Arm(s): REA | Intervention Type: PROCEDURE; Name: Suprageniculate femoropopliteal bypass; Assigned to Arm(s): Bypass
D: Arm Label: Open Bypass Surgery; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Open Bypass Surgery | Arm Label: Angioplasty and Stenting; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Angioplasty and Stenting | Intervention Type: PROCEDURE; Name: Open Bypass Surgery; Assigned to Arm(s): Open Bypass Surgery | Intervention Type: PROCEDURE; Name: Angioplasty and Stenting; Assigned to Arm(s): Angioplasty and Stenting

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: N/A
Brief Summary: Randomized control trial studying the effect of medical assistant health coaching for patients with diabetes, hypertension and hyperlipidemia within two San Francisco primary care community clinics, Mission Neighborhood Health Center and Southeast Health Center


Options:
A: Arm Label: Deprexis; Type: EXPERIMENTAL; Interventions: Behavioral: Deprexis | Arm Label: Wait-list; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Deprexis, Behavioral: Wait-list | Intervention Type: BEHAVIORAL; Name: Deprexis; Assigned to Arm(s): Deprexis, Wait-list | Intervention Type: BEHAVIORAL; Name: Wait-list; Assigned to Arm(s): Wait-list
B: Arm Label: Conventional care, controlgroup; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: integrated health care chain; Type: EXPERIMENTAL; Interventions: Other: integrated health care chain | Intervention Type: OTHER; Name: integrated health care chain; Assigned to Arm(s): integrated health care chain
C: Arm Label: Intervention; Type: EXPERIMENTAL; Interventions: Behavioral: Intensive diabetes self-management education | Arm Label: Control Group; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Enhanced standard diabetes education | Intervention Type: BEHAVIORAL; Name: Intensive diabetes self-management education; Assigned to Arm(s): Intervention | Intervention Type: BEHAVIORAL; Name: Enhanced standard diabetes education; Assigned to Arm(s): Control Group
D: Arm Label: Health Coaching; Type: EXPERIMENTAL; Interventions: Behavioral: Health coaching by medical assistants in primary care | Intervention Type: BEHAVIORAL; Name: Health coaching by medical assistants in primary care; Assigned to Arm(s): Health Coaching

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: N/A
Brief Summary: Randomized control trial studying the effect of medical assistant health coaching for patients with diabetes, hypertension and hyperlipidemia within two San Francisco primary care community clinics, Mission Neighborhood Health Center and Southeast Health Center


Options:
A: Arm Label: Conventional care, controlgroup; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: integrated health care chain; Type: EXPERIMENTAL; Interventions: Other: integrated health care chain | Intervention Type: OTHER; Name: integrated health care chain; Assigned to Arm(s): integrated health care chain
B: Arm Label: Self-management group workshops; Type: EXPERIMENTAL; Interventions: Behavioral: Self-management group workshops | Arm Label: No treament (wait-list control); Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Self-management group workshops; Assigned to Arm(s): Self-management group workshops
C: Arm Label: Health Coaching; Type: EXPERIMENTAL; Interventions: Behavioral: Health coaching by medical assistants in primary care | Intervention Type: BEHAVIORAL; Name: Health coaching by medical assistants in primary care; Assigned to Arm(s): Health Coaching
D: Arm Label: Community-based nurse care management; Type: EXPERIMENTAL; Interventions: Other: Community-based nurse care management | Arm Label: Usual care; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: Community-based nurse care management; Assigned to Arm(s): Community-based nurse care management

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Evaluation of the PneumRx, Inc. Lung Volume Reduction Coil for the Treatment of Emphysema
Brief Summary: The objective of this study is to demonstrate the safety of the PneumRx Lung Volume Reduction Coil (LVRC) in a population of patients with emphysema. The PneumRx, Inc. LVRC is a used as a less invasive alternative to lung volume reduction surgery. The PneumRx LVRC is designed as an alternative to lung volume reduction surgery, potentially achieving the desired reduction in lung volume limiting the risks associated with major surgery, such as illness or death. This device is deployed through a bronchoscope and requires no incision.


Options:
A: Arm Label: Medical management; Type: NO_INTERVENTION; Interventions: Device: IBV Valve | Intervention Type: DEVICE; Name: IBV Valve; Assigned to Arm(s): Medical management
B: Arm Label: permanent Coil(s) implant, QOL measure; Type: EXPERIMENTAL; Interventions: Device: Lung Volume Reduction Coil (LVRC), Device: Coils | Intervention Type: DEVICE; Name: Lung Volume Reduction Coil (LVRC); Assigned to Arm(s): permanent Coil(s) implant, QOL measure | Intervention Type: DEVICE; Name: Coils; Assigned to Arm(s): permanent Coil(s) implant, QOL measure
C: Intervention Type: DEVICE; Name: AeriSeal System; Assigned to Arm(s): N/A
D: Arm Label: 2; Type: SHAM_COMPARATOR; Interventions: Device: Sham control | Arm Label: 1; Type: EXPERIMENTAL; Interventions: Device: Exhale® Drug-Eluting Stent | Intervention Type: DEVICE; Name: Exhale® Drug-Eluting Stent; Assigned to Arm(s): 1 | Intervention Type: DEVICE; Name: Sham control; Assigned to Arm(s): 2

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Antenatal Late Preterm Steroids (ALPS): A Randomized Placebo-Controlled Trial
Brief Summary: This is a randomized placebo controlled trial to evaluate whether antenatal corticosteroids can decrease the rate of neonatal respiratory support, thus decreasing the rate of NICU admissions and improving short-term outcomes in the late preterm infant. The use of antenatal corticosteroids has been shown to be beneficial in women at risk for preterm delivery prior to 34 weeks but has not been evaluated in those likely to deliver in the late preterm period


Options:
A: Arm Label: Intervention; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Increasing use of Antenatal Corticosteroids (ACS) | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Increasing use of Antenatal Corticosteroids (ACS); Assigned to Arm(s): Intervention
B: Arm Label: ACS (Group 1); Type: ACTIVE_COMPARATOR; Interventions: Drug: Betamethason Sodium Phosphate | Arm Label: Placebo (Group 2); Type: PLACEBO_COMPARATOR; Interventions: Drug: Normal saline | Intervention Type: DRUG; Name: Betamethason Sodium Phosphate; Assigned to Arm(s): ACS (Group 1) | Intervention Type: DRUG; Name: Normal saline; Assigned to Arm(s): Placebo (Group 2)
C: Arm Label: Registry Cohort; Type: N/A; Interventions: Other: No Intervention | Intervention Type: OTHER; Name: No Intervention; Assigned to Arm(s): Registry Cohort
D: Arm Label: Betamethasone; Type: ACTIVE_COMPARATOR; Interventions: Drug: Betamethasone | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Betamethasone; Assigned to Arm(s): Betamethasone | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Antenatal Late Preterm Steroids (ALPS): A Randomized Placebo-Controlled Trial
Brief Summary: This is a randomized placebo controlled trial to evaluate whether antenatal corticosteroids can decrease the rate of neonatal respiratory support, thus decreasing the rate of NICU admissions and improving short-term outcomes in the late preterm infant. The use of antenatal corticosteroids has been shown to be beneficial in women at risk for preterm delivery prior to 34 weeks but has not been evaluated in those likely to deliver in the late preterm period


Options:
A: Arm Label: Betamethasone; Type: ACTIVE_COMPARATOR; Interventions: Drug: Betamethasone | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Betamethasone; Assigned to Arm(s): Betamethasone | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
B: Intervention Type: DRUG; Name: Betamethasone(Celestone soluspan) and Dexamethasone; Assigned to Arm(s): N/A
C: Arm Label: ACS (Group 1); Type: ACTIVE_COMPARATOR; Interventions: Drug: Betamethason Sodium Phosphate | Arm Label: Placebo (Group 2); Type: PLACEBO_COMPARATOR; Interventions: Drug: Normal saline | Intervention Type: DRUG; Name: Betamethason Sodium Phosphate; Assigned to Arm(s): ACS (Group 1) | Intervention Type: DRUG; Name: Normal saline; Assigned to Arm(s): Placebo (Group 2)
D: Arm Label: Intervention; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Increasing use of Antenatal Corticosteroids (ACS) | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Increasing use of Antenatal Corticosteroids (ACS); Assigned to Arm(s): Intervention

Answer: A